restricting the use of Tasmar (tolcapone) due to reports of serious liver toxicity

December 1998

The FDA and HPB are restricting the use of Tasmar (tolcapone) due to reports of serious liver toxicity...including three deaths.

Tasmar just came out last year. It's used to prolong the effect of levodopa in patients with advanced Parkinson's.

Now the FDA recommends limiting Tasmar to patients who can't take or don't respond to other Parkinson's drugs.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Practice $10 to get patients to bring in their recalled EpiPens
New guidelines for managing diabetes have just been released
Infectious Diseases new strengths of Clavulin
Infectious Diseases higher doses of amoxicillin for acute otitis media in children
Interactions add carbamazepine (Tegretol) to the list of drugs that can interact with grapefruit juice
Women's Health Two new topical estrogen products have just hit the market
Women's Health The National Cancer Institute is now offering a "Risk Disk"
Pediatrics Robi Comb, a small electronic comb to "zap" head lice
Pediatrics using secretin for autism
Neurology & Pain restricting the use of Tasmar (tolcapone) due to reports of serious liver toxicity
which antiepileptic drugs interact with oral contraceptives (OCs)
Substance Use Disorder people getting addicted to OTC stimulants
Substance Use Disorder loosen restrictions on the synthetic THC, Marinol (dronabinol)
new drugs on the horizon for rheumatoid arthritis
backlash against all the drug ads to consumers
new question about whether St. John's wort might cause nerve toxicity